Collaborate Explore Discover

Selected Major Grants and AwardsThe Molecular Genetics and Hematopoiesis Program has a funding base of $9,097,675 in annual total costs (current as of July2009). This sum includes $3,088,137 in NCI funding and $670,795 in other NIH funding. Due to space constraints, only newawards presented since January 1, 2008 with funding of $100,000 or more in annual total costs are listed here.Investigator Title Start DateLe Beau, MichelleThirman, MichaelKee, BarbaraChen, JianjunChen, JianjunSmith, SonaliLe Beau, MichelleRowley, JanetGounari, FotiniLarson, RichardEtiology of Alkylator-Induced MyeloidLeukemiaPeptide and Small MoleculeTherapeutics for HematologicMalignanciesRegulation of LymphocyteDevelopment by HLH ProteinsThe Role and Functional Mechanismof a miRNA Cluster, mir-17-92 inLeukemogenesis3UTR Variation of MicroRNA TargetsDuring Stem Cell Differentiation andHematopoiesisA Phase 1/2a Open-Label Studyof Praletrexate and Gemcitabinewith Vitamin B12 and Folic AcidSupplementation in Patientswith Relapsed or RefractoryLymphoproliferative MalignanciesMechanisms of TreatmentResponsiveness and Resistance inMyeloid MalignanciesComparisons of Microarray andMicroRNA for Diagnosis andPrognosisWnt/b-Catenin Signaling in T-CellTransformationA Multi-Center, Open Label, SingleArm Study of Weekly Alvocidib inPatients with Previously TreatedB-Cell Chronic LymphocyticLeukemia (CLL) or ProlymphocyticLeukemia (PLL) Arising from CLLEndDateAnnualTotal CostClassFunding Agency9/1/2008 8/31/2013 $1,667,989 PO1 National Cancer Institute10/1/2006 9/30/2011 $1,050,000 N/AThe Leukemia & LymphomaSociety7/3/2008 5/31/2013 $292,163 R01 National Cancer Institute6/1/2008 4/30/2013 $286,661 R01 National Cancer Institute7/1/2008 6/30/2011 $275,000 N/AMathers CharitableFoundation7/17/2008 7/16/2010 $241,344 N/A Allos Therrapeutics, Inc.10/1/2008 9/30/2013 $229,500 SCOR10/1/2008 9/30/2011 $200,000 N/AThe Leukemia & LymphomaSocietyThe Leukemia & LymphomaSociety5/1/2008 4/30/2010 $191,875 R21 National Institutes of Health4/14/2008 4/13/2010 $178,500 N/A Sanofi-Aventis U.S. Inc.Le Beau, Michelle Institutional Research Grant 1/1/2009 12/31/2011 $120,000 58 American Cancer SocietyGodley, LucyA Phase I, Multi-Dose Study ofSGN-33 (antiCD33 mAB, HuM195,lintuzumab) in Patients with6/25/2008 6/24/2010 $120,000 N/A Seattle Genetics, Inc.Acute Myeloid Leukemia andMyelodysplastic SyndromeStock, WendyA Phase 2/3 Study to Evaluate theSafety & Efficacy of Lumiliximabin Combination with Fludarabine,Cyclosphosphamide, and RituximabVs. Fludarabine, Cyclophosphamide,and Rituximab Alone in Subjectsw/Relapsed Chronic LymphocyticLukemia8/8/2008 8/7/2010 $116,000 N/A Biogen Idec Inc.Kee, BarbaraSmith, SonaliTranscriptional Deregulation andLymphocyte TransformationPhase I Dose-Escalation Study ofBruton's Tyrosine Kinase (Btk)Inhibitor PCI-32765 in Recurrent BCell Lymphoma7/1/2008 6/30/2013 $110,000 N/AThe Leukemia & LymphomaSociety10/30/2008 12/31/2009 $104,137 N/A Pharmacyclics, Inc.Molecular Genetics& HematopoiesisUCCRC SCIENTIFIC REPORT 200943